

Attorney Docket No.: ISPH-0767
Inventors: Baker et al.
Serial No.: 10/647,918
Filing Date: August 26, 2003
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-23 (canceled).

Claim 24 (new): A method of treating an inflammatory disorder in an individual comprising administering to said individual an effective amount of an antisense compound comprising at least an 8 nucleobase portion of SEQ ID NO: 432.

Claim 25 (new): The method of claim 24, wherein said antisense compound is an antisense oligonucleotide.

Claim 26 (new): The method of claim 25, wherein said antisense oligonucleotide comprises SEQ ID NO: 432.

Claim 27 (new): The method of claim 26, wherein said antisense oligonucleotide consists of SEQ ID NO: 432.

Claim 28 (new): The method of claim 25, wherein said antisense oligonucleotide is administered orally, topically or subcutaneously.

Claim 29 (new): The method of claim 25, wherein said antisense oligonucleotide comprises a modified internucleoside linkage.

Attorney Docket No.: **ISPH-0767**
Inventors: **Baker et al.**
Serial No.: **10/647,918**
Filing Date: **August 26, 2003**
Page 3

Claim 30 (new): The method of claim 29, wherein said internucleoside linkage is a phosphorothioate linkage.

Claim 31 (new): The method of claim 25, wherein said antisense oligonucleotide comprises a modified sugar.

Claim 32 (new): The method of claim 31, wherein the modified sugar is a 2'-MOE.

Claim 33 (new): The method of claim 25, wherein the antisense oligonucleotide comprises a modified base.

Claim 34 (new): The method of claim 33, wherein the modified base is a 5-methyl cytidine.

Claim 35 (new): The method of claim 24, wherein said inflammatory disorder is rheumatoid arthritis.

Claim 36 (new): An antisense oligonucleotide consisting of SEQ ID NO: 432, wherein every internucleoside linkage is a phosphodiester linkage, nucleotides 1-5 and 16-20 comprise a 2'-MOE modification and all cytidine bases are 5-methyl cytidines, or a pharmaceutically acceptable salt thereof.

Claim 37 (new): The antisense oligonucleotide of claim 36 wherein the salt is a sodium salt.

Attorney Docket No.: ISPH-0767
Inventors: Baker et al.
Serial No.: 10/647,918
Filing Date: August 26, 2003
Page 4

Claim 38 (new): A composition comprising the antisense oligonucleotide of claim 36 and a pharmaceutically acceptable carrier, excipient or diluent.